1.43
-0.0019(-0.13%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.4 |
| Day High | 1.43 |
| Day Low | 1.4 |
| 52-Week High | 1.75 |
| 52-Week Low | 0.65 |
| Volume | 15,800 |
| Average Volume | 387,646 |
| Market Cap | 85.55M |
| PE | -0.76 |
| EPS | -1.88 |
| Moving Average 50 Days | 1.19 |
| Moving Average 200 Days | 1.07 |
| Change | -0 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $17,851.25 as of September 18, 2025 at a share price of $1.428. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,107.05 as of September 18, 2025 at a share price of $1.428.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other op
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal disea
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Robert Gagnon, CFO, Opus Genetics Robert Gagnon, CFO, Opus Genetics RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inh